Document is current
Any future updates will be listed below
-
Authors
Ohta, Yoshinori
Miyamoto, Kyohei
Kawazoe, Yu
Yamamura, Hitoshi
Morimoto, Takeshi http://orcid.org/0000-0002-6844-739X
-
Funding
Funding for this research was provided by:
Hospira (NA)
Japan Society for the Promotion of Science (JP17K09252, JP25860484, JP15K21535, JP17689022, JP21659130, JP22390103, JP23659256, JP26293159)
Japan Society for the Promotion of Science (JP20K07839)
- License Information
-
More Information
Article History
Received: 8 February 2020
Accepted: 27 July 2020
First Online: 10 August 2020
Ethics approval and consent to participate
: This study was approved by the institutional review boards of Wakayama Medical University and each participating institution. Written informed consent was obtained from the patient or patient’s family before randomization.
: Not applicable.
: Dr. Ohta has no conflicts of interest. Dr. Miyamoto received lecture fees from Becton Dickinson and Pfizer Japan. Dr. Kawazoe received lecture fees from Hospira Japan and Pfizer Japan and a scholarship from Hospira Japan. Dr. Yamamura received lecture fees from Hospira Japan, Nipro, and Asahi Kasei and educational consulting fees from Toray Industries, CSL Behring, Teijin Pharma, and Nihon Pharmaceutical. Dr. Morimoto received lecture fees from Bayer, Daiichi Sankyo, Japan Lifeline, Kyocera, Mitsubishi Tanabe, Novartis, and Pfizer Japan; a manuscript fee from Pfizer Japan; and consulting fees from Asahi Kasei, Bristol-Myers Squibb, and Boston Scientific.
